Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14


A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development.

Spiros A, Geerts H.

J Exp Pharmacol. 2012 Apr 30;4:53-61. doi: 10.2147/JEP.S30808. eCollection 2012.


Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers.

Ashare RL, Kimmey BA, Rupprecht LE, Bowers ME, Hayes MR, Schmidt HD.

Transl Psychiatry. 2016 Jan 19;6:e713. doi: 10.1038/tp.2015.209. Erratum in: Transl Psychiatry. 2017 Mar 28;7(3):e1072.


Advances in recent patent and clinical trial drug development for Alzheimer's disease.

Liu H, Wang L, Su W, Xie XQ.

Pharm Pat Anal. 2014 Jul;3(4):429-47. doi: 10.4155/ppa.14.22. Review.


Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.

Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G.

Transl Psychiatry. 2013 Dec 3;3:e332. doi: 10.1038/tp.2013.97. Review.


Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability.

Weisová P, Alvarez SP, Kilbride SM, Anilkumar U, Baumann B, Jordán J, Bernas T, Huber HJ, Düssmann H, Prehn JH.

Transl Psychiatry. 2013 Oct 22;3:e317. doi: 10.1038/tp.2013.92.


Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats.

Kimmey BA, Rupprecht LE, Hayes MR, Schmidt HD.

Addict Biol. 2014 Jul;19(4):539-51. doi: 10.1111/adb.12014. Epub 2012 Dec 12.


Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.

Bharadwaj PR, Verdile G, Barr RK, Gupta V, Steele JW, Lachenmayer ML, Yue Z, Ehrlich ME, Petsko G, Ju S, Ringe D, Sankovich SE, Caine JM, Macreadie IG, Gandy S, Martins RN.

J Alzheimers Dis. 2012;32(4):949-67. doi: 10.3233/JAD-2012-120178.


Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain.

Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Protter AA, Martins RN, Ehrlich ME, Yue Z, Petsko GA, Gandy S.

Mol Psychiatry. 2013 Aug;18(8):882-8. doi: 10.1038/mp.2012.115. Epub 2012 Aug 7.


Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model.

Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA, Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S.

Mol Psychiatry. 2013 Aug;18(8):889-97. doi: 10.1038/mp.2012.106. Epub 2012 Jul 31.


Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA, Schmidt HD.

Neuropsychopharmacology. 2012 Sep;37(10):2310-21. doi: 10.1038/npp.2012.83. Epub 2012 Jun 6.


Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice.

Bachurin SO, Shelkovnikova TA, Ustyugov AA, Peters O, Khritankova I, Afanasieva MA, Tarasova TV, Alentov II, Buchman VL, Ninkina NN.

Neurotox Res. 2012 Jul;22(1):33-42. doi: 10.1007/s12640-011-9299-y. Epub 2011 Dec 17.


Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.

Shelkovnikova TA, Ustyugov AA, Millership S, Peters O, Anichtchik O, Spillantini MG, Buchman VL, Bachurin SO, Ninkina NN.

Neurodegener Dis. 2011;8(6):430-7. doi: 10.1159/000324989. Epub 2011 May 12.


The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys.

Webster SJ, Wilson CA, Lee CH, Mohler EG, Terry AV Jr, Buccafusco JJ.

Br J Pharmacol. 2011 Oct;164(3):970-8. doi: 10.1111/j.1476-5381.2011.01432.x.


Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease.

Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M, Zhao W, Ho L, Pasinetti GM.

Mol Neurodegener. 2011 Jan 19;6(1):7. doi: 10.1186/1750-1326-6-7.

Supplemental Content

Support Center